TQ-BIRD: a databank linking tumor control, treatment side effects, quality of life, and biomarkers for cancer patients
Official title: Tumor Control, Treatment Toxicity, Quality of Life and Bio-Imaging Repository Databank (TQ-BIRD) for Cancer Patients-A Master Protocol for Imaging and Blood Biomarker Group
Run by The University of Hong Kong-Shenzhen Hospital · NCT05061342 · Data updated 2026-11-12
This project will collect blood, imaging, and tissue samples from adult cancer patients to see if biomarker patterns relate to tumor control, treatment side effects, and quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | The University of Hong Kong-Shenzhen Hospital Academic / other |
| Locations | 1 site (Shenzhen, Guangdong) |
| Status | Recruiting |
| Started | June 27, 2019 |
| Main results expected | December 31, 2029 |
| Study ends | December 31, 2029 |
| Registry record updated | January 27, 2026 |
| Trial ID | NCT05061342 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with cancer who are scheduled to receive surgery, systemic therapy, radiotherapy or other anticancer care at the participating centers, as well as healthy adult volunteers without active cancer, are ideal candidates.
✕Probably not a fit
Patients under 18, those who cannot complete quality-of-life questionnaires, or people not treated at the participating centers are unlikely to benefit from participating.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational databank prospectively collects clinical data, imaging, blood and other minimally invasive biomarker samples, and residual tumor tissue when available from adults receiving any anticancer therapy at participating centers. Tumor response will be classified by RECIST, quality of life by PROMIS, and immune/inflammatory biomarkers (for example lymphocyte subsets, TGF-beta1, interleukins, and IDO metabolites) will be measured before, during, and after therapy. Collected specimens and linked clinical/imaging data will be stored for hypothesis-driven analyses and for use by junior investigators. The project includes healthy adult controls for baseline comparisons and aims to enable correlations between biomarkers, treatment toxicity, tumor control, survival, and patient-reported outcomes.
Why it matters
Potential benefit: If successful, the databank could help predict who is most likely to respond to specific treatments or suffer severe side effects, enabling more personalized cancer care.
How similar studies have gone: Previous biomarker-outcome studies—especially those focused on immune markers—have shown promising signals, but comprehensive repositories that link imaging, tissue, blood, and patient-reported QoL data remain relatively uncommon.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Cancer Patients * 18 years of age and older. * Scheduled to receive any kind of therapy in our center. * Performance status of ECOG 0, 1, 2, or 3. * Able to understand QoL questionnaire. Normal (non cancer) controls * 18 years of age and older healthy volunteers. * Without a history of cancer except for cured skin cancer, without any active cancer. * ECOG Performance status 0, 1, 2, or 3. Exclusion Criteria: Participants who have supposedly limited ability to complete the survey questionnaires of the present study will be excluded.
Where it's running
-
UHongKongShenzhen
Shenzhen, Guangdong, China Recruiting
Study contacts
- Principal investigator: Feng-Ming (Spring) KONG, Professor — The University of Hong Kong-Shenzhen Hospital
- Study coordinator: Li YANG, Dr.
- Email: yangl1@hku-szh.org
- Phone: 0755-86913333-2107
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.